Clinical Edge Journal Scan

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791

Key clinical point: In patients with early breast cancer (BC) who were undergoing breast-conserving surgery and sentinel lymph node detection (SLND), a combination of paramagnetic seed + superparamagnetic iron oxide (SPIO) led to comparable rates of re-excision and resection ratios as the more standard approach with guidewire + SPIO.

Major finding: Paramagnetic seed + SPIO and guidewire + SPIO showed comparable re-excision rates (2.87% vs 2.84%; P = .99) and median resection ratios (2.01 vs 1.93; P = .70). The rate of failed breast lesion localizations was significantly more in the guidewire vs paramagnetic seed group (10.1% vs 1.9%; P < .001).

Study details: Findings are from the phase 3 MAGTOTAL trial that included 426 patients with early BC scheduled to undergo breast-conserving surgery and SLND who were randomly assigned to either lesion localization using paramagnetic seed + SPIO or guidewire + SPIO.

Disclosures: This study was supported partly by Uppsala University Hospital. Sweden, and institutional grants from Uppsala University and other sources. A Karakatsanis declared receiving grants and honoraria from various sources outside the study.

Source: Pantiora E et al. Magnetic seed vs guidewire breast cancer localization with magnetic lymph node detection: A randomized clinical trial. JAMA Surg. 2023 (Dec 27). doi: 10.1001/jamasurg.2023.6520

Key clinical point: In patients with early breast cancer (BC) who were undergoing breast-conserving surgery and sentinel lymph node detection (SLND), a combination of paramagnetic seed + superparamagnetic iron oxide (SPIO) led to comparable rates of re-excision and resection ratios as the more standard approach with guidewire + SPIO.

Major finding: Paramagnetic seed + SPIO and guidewire + SPIO showed comparable re-excision rates (2.87% vs 2.84%; P = .99) and median resection ratios (2.01 vs 1.93; P = .70). The rate of failed breast lesion localizations was significantly more in the guidewire vs paramagnetic seed group (10.1% vs 1.9%; P < .001).

Study details: Findings are from the phase 3 MAGTOTAL trial that included 426 patients with early BC scheduled to undergo breast-conserving surgery and SLND who were randomly assigned to either lesion localization using paramagnetic seed + SPIO or guidewire + SPIO.

Disclosures: This study was supported partly by Uppsala University Hospital. Sweden, and institutional grants from Uppsala University and other sources. A Karakatsanis declared receiving grants and honoraria from various sources outside the study.

Source: Pantiora E et al. Magnetic seed vs guidewire breast cancer localization with magnetic lymph node detection: A randomized clinical trial. JAMA Surg. 2023 (Dec 27). doi: 10.1001/jamasurg.2023.6520

Key clinical point: In patients with early breast cancer (BC) who were undergoing breast-conserving surgery and sentinel lymph node detection (SLND), a combination of paramagnetic seed + superparamagnetic iron oxide (SPIO) led to comparable rates of re-excision and resection ratios as the more standard approach with guidewire + SPIO.

Major finding: Paramagnetic seed + SPIO and guidewire + SPIO showed comparable re-excision rates (2.87% vs 2.84%; P = .99) and median resection ratios (2.01 vs 1.93; P = .70). The rate of failed breast lesion localizations was significantly more in the guidewire vs paramagnetic seed group (10.1% vs 1.9%; P < .001).

Study details: Findings are from the phase 3 MAGTOTAL trial that included 426 patients with early BC scheduled to undergo breast-conserving surgery and SLND who were randomly assigned to either lesion localization using paramagnetic seed + SPIO or guidewire + SPIO.

Disclosures: This study was supported partly by Uppsala University Hospital. Sweden, and institutional grants from Uppsala University and other sources. A Karakatsanis declared receiving grants and honoraria from various sources outside the study.

Source: Pantiora E et al. Magnetic seed vs guidewire breast cancer localization with magnetic lymph node detection: A randomized clinical trial. JAMA Surg. 2023 (Dec 27). doi: 10.1001/jamasurg.2023.6520

Key clinical point: Induction treatment with bevacizumab, etoposide, and cisplatin (BEEP) before whole-brain radiotherapy (WBRT) vs WBRT alone improved brain-specific progression-free survival (PFS) outcomes in patients with brain metastases from breast cancer (BMBC).

Major finding: Patients who received BEEP + WBRT vs WBRT alone had significantly longer median brain-specific PFS based on a predefined α level of ≤0.20 (8.1 vs 6.5 months; hazard ratio 0.71; P = .15) and higher 8-month brain-specific PFS rate (48.7% vs 26.3%; P = .03). Neutropenia, nausea, anemia, and leukopenia were the most common adverse events in the BEEP induction arm.

Study details: Findings are from the phase 2 A-PLUS trial that included 118 WBRT-naive patients with invasive breast cancer who had ≥1 metastatic brain tumors and were randomly assigned to receive BEEP induction followed by WBRT or only WBRT.

Disclosures: This study received investigational product support and grants funding from Roche Taiwan, Chugai Pharma Taiwan, and other sources. Four authors declared receiving personal fees, lecture fees, consulting or speakers’ bureau fees, travel support, or grants from Roche and other sources.

Source: Chen TW et al. Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: A randomized clinical trial. JAMA Oncol. 2023 (Dec 21). doi: 10.1001/jamaoncol.2023.5456

Key clinical point: Induction treatment with bevacizumab, etoposide, and cisplatin (BEEP) before whole-brain radiotherapy (WBRT) vs WBRT alone improved brain-specific progression-free survival (PFS) outcomes in patients with brain metastases from breast cancer (BMBC).

Major finding: Patients who received BEEP + WBRT vs WBRT alone had significantly longer median brain-specific PFS based on a predefined α level of ≤0.20 (8.1 vs 6.5 months; hazard ratio 0.71; P = .15) and higher 8-month brain-specific PFS rate (48.7% vs 26.3%; P = .03). Neutropenia, nausea, anemia, and leukopenia were the most common adverse events in the BEEP induction arm.

Study details: Findings are from the phase 2 A-PLUS trial that included 118 WBRT-naive patients with invasive breast cancer who had ≥1 metastatic brain tumors and were randomly assigned to receive BEEP induction followed by WBRT or only WBRT.

Disclosures: This study received investigational product support and grants funding from Roche Taiwan, Chugai Pharma Taiwan, and other sources. Four authors declared receiving personal fees, lecture fees, consulting or speakers’ bureau fees, travel support, or grants from Roche and other sources.

Source: Chen TW et al. Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: A randomized clinical trial. JAMA Oncol. 2023 (Dec 21). doi: 10.1001/jamaoncol.2023.5456

Key clinical point: Induction treatment with bevacizumab, etoposide, and cisplatin (BEEP) before whole-brain radiotherapy (WBRT) vs WBRT alone improved brain-specific progression-free survival (PFS) outcomes in patients with brain metastases from breast cancer (BMBC).

Major finding: Patients who received BEEP + WBRT vs WBRT alone had significantly longer median brain-specific PFS based on a predefined α level of ≤0.20 (8.1 vs 6.5 months; hazard ratio 0.71; P = .15) and higher 8-month brain-specific PFS rate (48.7% vs 26.3%; P = .03). Neutropenia, nausea, anemia, and leukopenia were the most common adverse events in the BEEP induction arm.

Study details: Findings are from the phase 2 A-PLUS trial that included 118 WBRT-naive patients with invasive breast cancer who had ≥1 metastatic brain tumors and were randomly assigned to receive BEEP induction followed by WBRT or only WBRT.

Disclosures: This study received investigational product support and grants funding from Roche Taiwan, Chugai Pharma Taiwan, and other sources. Four authors declared receiving personal fees, lecture fees, consulting or speakers’ bureau fees, travel support, or grants from Roche and other sources.

Source: Chen TW et al. Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: A randomized clinical trial. JAMA Oncol. 2023 (Dec 21). doi: 10.1001/jamaoncol.2023.5456

Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).

Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.

Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.

Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424

Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).

Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.

Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.

Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424

Key clinical point: Adding atezolizumab to carboplatin improved overall survival (OS) outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Compared with carboplatin alone, carboplatin + atezolizumab demonstrated significant improvement in OS outcomes (hazard ratio [HR] 0.60; log-rank P = .03) even though the improvement in the primary endpoint of progression-free survival was not statistically significant (HR 0.66; log-rank P = .05). The prevalence of grade 3/4 serious adverse events was higher with carboplatin + atezolizumab vs carboplatin alone (41% vs 8%).

Study details: Findings are from the phase 2 TBCRC 043 trial that included 106 patients with metastatic TNBC who were randomly assigned to receive either carboplatin alone or in combination with atezolizumab.

Disclosures: This study was supported by a US National Cancer Institute grant, Susan G. Komen grants, and other sources. Some authors declared receiving grants or personal fees from or having other ties with various sources, including the funding agencies.

Source: Lehmann BD et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2023 (Dec 14). doi: 10.1001/jamaoncol.2023.5424

Key clinical point: Compared with the general population, the risk for overall breast cancer (BC) was nearly double in women with benign breast disease (BBD) diagnosed by percutaneous biopsies.

Major finding: Patients with BBD vs the general population were at a significantly higher risk for overall BC (standard incidence ratio [SIR] 1.95; 95% CI 1.76-2.17), including invasive BC (SIR 1.56; 95% CI 1.37-1.78) and ductal carcinoma in situ (SIR 3.10; 95% CI 2.54-3.77). The SIR for overall BC increased progressively with increasing BBD severity (nonproliferative 1.42; 95% CI 1.19-1.71; proliferative disease without atypia 2.19; 95% CI 1.88-2.54; atypical hyperplasia 3.91; 95% CI 2.97-5.14).

Study details: Findings are from a retrospective cohort study including 4819 female patients who underwent a BBD biopsy, of whom 338 patients had incident BC.

Disclosures: This study was supported by a grant from the US National Institutes of Health (NIH). Four authors declared receiving grants, research support, or personal fees from NIH and other sources.

Source: Sherman ME et al. Benign breast disease and breast cancer risk in the percutaneous biopsy era. JAMA Surg. 2023 (Dec 13). doi: 10.1001/jamasurg.2023.6382

Key clinical point: Compared with the general population, the risk for overall breast cancer (BC) was nearly double in women with benign breast disease (BBD) diagnosed by percutaneous biopsies.

Major finding: Patients with BBD vs the general population were at a significantly higher risk for overall BC (standard incidence ratio [SIR] 1.95; 95% CI 1.76-2.17), including invasive BC (SIR 1.56; 95% CI 1.37-1.78) and ductal carcinoma in situ (SIR 3.10; 95% CI 2.54-3.77). The SIR for overall BC increased progressively with increasing BBD severity (nonproliferative 1.42; 95% CI 1.19-1.71; proliferative disease without atypia 2.19; 95% CI 1.88-2.54; atypical hyperplasia 3.91; 95% CI 2.97-5.14).

Study details: Findings are from a retrospective cohort study including 4819 female patients who underwent a BBD biopsy, of whom 338 patients had incident BC.

Disclosures: This study was supported by a grant from the US National Institutes of Health (NIH). Four authors declared receiving grants, research support, or personal fees from NIH and other sources.

Source: Sherman ME et al. Benign breast disease and breast cancer risk in the percutaneous biopsy era. JAMA Surg. 2023 (Dec 13). doi: 10.1001/jamasurg.2023.6382

Key clinical point: Compared with the general population, the risk for overall breast cancer (BC) was nearly double in women with benign breast disease (BBD) diagnosed by percutaneous biopsies.

Major finding: Patients with BBD vs the general population were at a significantly higher risk for overall BC (standard incidence ratio [SIR] 1.95; 95% CI 1.76-2.17), including invasive BC (SIR 1.56; 95% CI 1.37-1.78) and ductal carcinoma in situ (SIR 3.10; 95% CI 2.54-3.77). The SIR for overall BC increased progressively with increasing BBD severity (nonproliferative 1.42; 95% CI 1.19-1.71; proliferative disease without atypia 2.19; 95% CI 1.88-2.54; atypical hyperplasia 3.91; 95% CI 2.97-5.14).

Study details: Findings are from a retrospective cohort study including 4819 female patients who underwent a BBD biopsy, of whom 338 patients had incident BC.

Disclosures: This study was supported by a grant from the US National Institutes of Health (NIH). Four authors declared receiving grants, research support, or personal fees from NIH and other sources.

Source: Sherman ME et al. Benign breast disease and breast cancer risk in the percutaneous biopsy era. JAMA Surg. 2023 (Dec 13). doi: 10.1001/jamasurg.2023.6382

Key clinical point: A significant association was observed between atopic dermatitis (AD) and poorer cognitive function in men, and familial characteristics exerted a confounding effect on this association.

Major finding: After effectively controlling for familial environmental confounding factors and addressing genetic influences, AD in men was significantly associated with poorer cognitive function (regression coefficient −0.04; 95% CI −0.07 to −0.003).

Study details: This sibling-comparison study included 1,687,038 men who underwent a military conscription examination at 17-22 years of age, of which 25,995 were diagnosed with AD.

Disclosures: This study was sponsored by grants from the Swedish Research Council for Health, Working Life, and Welfare (Forte) and the UK Economic and Social Research Council. L von Kobyletzki declared being a consultant for and receiving research funding from various organizations. The other authors declared no conflicts of interest.

Source: Smith KA et al. Atopic dermatitis and cognitive function: A sibling comparison study among males in Sweden. Br J Dermatol. 2024 (Jan 3). doi: 10.1093/bjd/ljae004

Key clinical point: A significant association was observed between atopic dermatitis (AD) and poorer cognitive function in men, and familial characteristics exerted a confounding effect on this association.

Major finding: After effectively controlling for familial environmental confounding factors and addressing genetic influences, AD in men was significantly associated with poorer cognitive function (regression coefficient −0.04; 95% CI −0.07 to −0.003).

Study details: This sibling-comparison study included 1,687,038 men who underwent a military conscription examination at 17-22 years of age, of which 25,995 were diagnosed with AD.

Disclosures: This study was sponsored by grants from the Swedish Research Council for Health, Working Life, and Welfare (Forte) and the UK Economic and Social Research Council. L von Kobyletzki declared being a consultant for and receiving research funding from various organizations. The other authors declared no conflicts of interest.

Source: Smith KA et al. Atopic dermatitis and cognitive function: A sibling comparison study among males in Sweden. Br J Dermatol. 2024 (Jan 3). doi: 10.1093/bjd/ljae004

Key clinical point: A significant association was observed between atopic dermatitis (AD) and poorer cognitive function in men, and familial characteristics exerted a confounding effect on this association.

Major finding: After effectively controlling for familial environmental confounding factors and addressing genetic influences, AD in men was significantly associated with poorer cognitive function (regression coefficient −0.04; 95% CI −0.07 to −0.003).

Study details: This sibling-comparison study included 1,687,038 men who underwent a military conscription examination at 17-22 years of age, of which 25,995 were diagnosed with AD.

Disclosures: This study was sponsored by grants from the Swedish Research Council for Health, Working Life, and Welfare (Forte) and the UK Economic and Social Research Council. L von Kobyletzki declared being a consultant for and receiving research funding from various organizations. The other authors declared no conflicts of interest.

Source: Smith KA et al. Atopic dermatitis and cognitive function: A sibling comparison study among males in Sweden. Br J Dermatol. 2024 (Jan 3). doi: 10.1093/bjd/ljae004

Key clinical point: Patients with atopic dermatitis (AD), especially moderate-to-severe AD, had an increased prevalence of inflammatory bowel disease (IBD).

Major finding: A significant association was observed between IBD and AD (adjusted odds ratio [aOR] 3.89; P = .0169); however, when stratified by AD severity, only moderate-to-severe AD was found to be associated with IBD (aOR 4.45; P = .0102).

Study details: Findings are from a retrospective observational study including 364 patients with AD and 725 matched control individuals without AD.

Disclosures: This study was sponsored by an independent investigator grant from AbbVie. Two authors declared serving as investigators for or receiving honoraria or fees as consultants or advisory board members from various organizations, including AbbVie. The other authors declared no conflicts of interest.

Source: Rom H et al. The association between atopic dermatitis and inflammatory bowel disease in adults: A cross-sectional study in a specialized atopic dermatitis clinic. J Eur Acad Dermatol Venereol. 2023 (Dec 21). doi: 10.1111/jdv.19769

Key clinical point: Patients with atopic dermatitis (AD), especially moderate-to-severe AD, had an increased prevalence of inflammatory bowel disease (IBD).

Major finding: A significant association was observed between IBD and AD (adjusted odds ratio [aOR] 3.89; P = .0169); however, when stratified by AD severity, only moderate-to-severe AD was found to be associated with IBD (aOR 4.45; P = .0102).

Study details: Findings are from a retrospective observational study including 364 patients with AD and 725 matched control individuals without AD.

Disclosures: This study was sponsored by an independent investigator grant from AbbVie. Two authors declared serving as investigators for or receiving honoraria or fees as consultants or advisory board members from various organizations, including AbbVie. The other authors declared no conflicts of interest.

Source: Rom H et al. The association between atopic dermatitis and inflammatory bowel disease in adults: A cross-sectional study in a specialized atopic dermatitis clinic. J Eur Acad Dermatol Venereol. 2023 (Dec 21). doi: 10.1111/jdv.19769

Key clinical point: Patients with atopic dermatitis (AD), especially moderate-to-severe AD, had an increased prevalence of inflammatory bowel disease (IBD).

Major finding: A significant association was observed between IBD and AD (adjusted odds ratio [aOR] 3.89; P = .0169); however, when stratified by AD severity, only moderate-to-severe AD was found to be associated with IBD (aOR 4.45; P = .0102).

Study details: Findings are from a retrospective observational study including 364 patients with AD and 725 matched control individuals without AD.

Disclosures: This study was sponsored by an independent investigator grant from AbbVie. Two authors declared serving as investigators for or receiving honoraria or fees as consultants or advisory board members from various organizations, including AbbVie. The other authors declared no conflicts of interest.

Source: Rom H et al. The association between atopic dermatitis and inflammatory bowel disease in adults: A cross-sectional study in a specialized atopic dermatitis clinic. J Eur Acad Dermatol Venereol. 2023 (Dec 21). doi: 10.1111/jdv.19769

Key clinical point: The majority of tralokinumab-treated patients with moderate-to-severe atopic dermatitis (AD) attained physician- and patient-reported outcomes over 32 weeks of observation, highlighting the multidimensional efficacy of tralokinumab in real-world settings.

Major finding: The proportion of patients achieving a ≥75% improvement in the baseline Eczema Area and Severity Index (EASI) score increased significantly from 42% at week 4 to 76% at week 32 (P = .0075). A similar trend was observed for patient-reported outcomes. At week 16, at least one real-world therapeutic endpoint was achieved by 88% of patients treated with tralokinumab.

Study details: Findings are from a multicenter real-world retrospective cohort study including 194 patients with moderate-to-severe AD who were treated with tralokinumab for ≥16 weeks.

Disclosures: This study did not receive any funding. Several authors declared serving as speakers, consultants, or scientific advisors; receiving personal fees, speaker’s honoraria, or travel support, or having other ties with various pharmaceutical companies.

Source: Chiricozzi A et al for the MEDaCoTRA Study Group. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: Results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307-1315 (Dec 18). doi: 10.1080/14712598.2023.2292627

Key clinical point: The majority of tralokinumab-treated patients with moderate-to-severe atopic dermatitis (AD) attained physician- and patient-reported outcomes over 32 weeks of observation, highlighting the multidimensional efficacy of tralokinumab in real-world settings.

Major finding: The proportion of patients achieving a ≥75% improvement in the baseline Eczema Area and Severity Index (EASI) score increased significantly from 42% at week 4 to 76% at week 32 (P = .0075). A similar trend was observed for patient-reported outcomes. At week 16, at least one real-world therapeutic endpoint was achieved by 88% of patients treated with tralokinumab.

Study details: Findings are from a multicenter real-world retrospective cohort study including 194 patients with moderate-to-severe AD who were treated with tralokinumab for ≥16 weeks.

Disclosures: This study did not receive any funding. Several authors declared serving as speakers, consultants, or scientific advisors; receiving personal fees, speaker’s honoraria, or travel support, or having other ties with various pharmaceutical companies.

Source: Chiricozzi A et al for the MEDaCoTRA Study Group. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: Results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307-1315 (Dec 18). doi: 10.1080/14712598.2023.2292627

Key clinical point: The majority of tralokinumab-treated patients with moderate-to-severe atopic dermatitis (AD) attained physician- and patient-reported outcomes over 32 weeks of observation, highlighting the multidimensional efficacy of tralokinumab in real-world settings.

Major finding: The proportion of patients achieving a ≥75% improvement in the baseline Eczema Area and Severity Index (EASI) score increased significantly from 42% at week 4 to 76% at week 32 (P = .0075). A similar trend was observed for patient-reported outcomes. At week 16, at least one real-world therapeutic endpoint was achieved by 88% of patients treated with tralokinumab.

Study details: Findings are from a multicenter real-world retrospective cohort study including 194 patients with moderate-to-severe AD who were treated with tralokinumab for ≥16 weeks.

Disclosures: This study did not receive any funding. Several authors declared serving as speakers, consultants, or scientific advisors; receiving personal fees, speaker’s honoraria, or travel support, or having other ties with various pharmaceutical companies.

Source: Chiricozzi A et al for the MEDaCoTRA Study Group. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: Results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307-1315 (Dec 18). doi: 10.1080/14712598.2023.2292627